The Duke-Margolis Institute for Health Policy, under a cooperative agreement with the U.S. FDA, is co-convening the Rare Disease Innovation, Science, and Exploration (RISE) Workshop series with the Rare Disease Innovation Hub. With many rare diseases lacking approved therapies these patient populations face unique challenges to medical product development, including small patient populations,...

The Duke-Margolis Institute for Health Policy, under a cooperative agreement with the U.S. FDA, is...

Reliable drug supply, Valuing availability, Advanced Manufacturing Technologies, and Patient-Center Focus (ReVAMP) The Consortium’s mission is to identify effective policy solutions that promote a resilient drug supply chain with advanced manufacturing capabilities and, ultimately, reduce the frequency and severity of drug shortages. Based on input from a wide range of experts involved in...

Reliable drug supply, Valuing availability, Advanced Manufacturing Technologies, and Patient-Center...

Duke-Margolis AI researchers are devoted to harnessing the potential of safe, trustworthy, and responsible AI to transform health care

Duke-Margolis AI researchers are devoted to harnessing the potential of safe, trustworthy, and...